JBPHF

Jacobio Pharmaceuticals Group Co. Ltd.

JBPHF, USA

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C reactivator, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumors and hematological malignancies. The company also develops IND-enabling candidates comprising JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with Merck for combination trials of cetuximab. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.

https://www.jacobiopharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2023-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.52

Low ≤ 1

High ≥ 3

Debt to Equity

-

Very High

0.26

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Jacobio Pharmaceuticals Group Co. Ltd.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

—

EPS Actual

—

EPS Estimate

—

EPS Difference

—

Surprise Percent

undefined%

Investing Fit Scorecard

(Last Updated 2023-06-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.5)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(2)
Value
Fair Value(6)

Income Statement

(Last Updated 2023-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2023-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.